> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Fulcrum Shareholders Would Keep About 5% Of A Migraine Drug Developer, Plus A $270 Million Dividend
- URL: https://www.bullished.co/fulcrum-shareholders-would-keep-about-5-of-a-migraine-drug-developer-plus-a-270-million-9b730808/
- Published: 2026-11-03T13:44:24.000Z
- Updated: 2026-11-05T18:37:25.000Z
- Description: Fulcrum's amended merger filing with Slate Medicines shows a $270.5 million dividend and a December 3 shareholder vote.
- Author: Matteo Parrino
- Tags: Deals, FULC, Industry: Healthcare

[Fulcrum Therapeutics](https://www.bullished.co/tag/fulc/) shareholders would hold about 5% of the combined company after its merger with Slate Medicines, plus a special cash dividend of about $270 million, according to an [amended SEC registration statement](https://www.sec.gov/Archives/edgar/data/0001680581/000119312526444432/d127837ds4a.htm?ref=bullished.co) filed Tuesday. Fulcrum, a clinical-stage drug developer, has wound down after the FDA's concerns ended its sickle cell program, and the deal would turn the shell into a migraine-prevention company run by Slate management.

## Exchange ratio and the dividend

The all-stock deal sets an estimated exchange ratio of about 24.8186 Fulcrum shares per Slate common share, before a reverse split of 1-for-10 to 1-for-80\. There is no collar, so the ratio does not move with Fulcrum's stock price, only with Fulcrum's net cash.

The ratio rests on a $31.3 million valuation for Fulcrum, which assumes net cash of $20.3 million after the dividend. Slate is valued at $350 million before a concurrent $245 million investment, about $160 million of it expected from existing investors. Fulcrum holders of record would receive the dividend; the pro forma assumes $270.5 million.

On a fully diluted basis, Slate holders other than the new investors would own about 55.9%, the investors about 39.1% and Fulcrum holders about 5.0%. Leerink Partners, Fulcrum's financial adviser, put the value to Fulcrum holders (dividend plus retained shares) at about $3.93 per share, against a $3.78 present value of dissolution. Fulcrum closed at $3.74 on August 14.

## A pro forma balance sheet

The illustrative combined company would hold $394.848 million in cash and equivalents as of June 30, 2026, and report a net loss of $60.727 million for the first six months of 2026\. Those pro forma figures leave out integration costs. Slate's own transaction costs of $8.7 million reduce additional paid-in capital rather than earnings.

Fulcrum alone had $318.8 million in cash and marketable securities at June 30, and cut its workforce about 85%, from 57 employees to 9, at a restructuring cost of about $4.3 million. Slate, which reported a $15.7 million net loss for the six months, says the investment funds it into 2029.

## From sickle cell to migraine

Fulcrum's board concluded that no alternative would beat Slate, including continuing alone or liquidating. It contacted 62 counterparties and received 13 indications of interest.

Slate's lead candidate, SLTE-1009, is an antibody in a Phase 1 trial in Australia since August 2026, with topline data targeted for mid-2027\. A second, bispecific antibody is targeted for Phase 1 in the second half of 2027\. The filing cites forecasts of about $10 billion in peak sales for the CGRP migraine class in 2030\. It also flags that SLTE-1009 is untested in humans and that Lundbeck's rival is in Phase 3.

The company would be renamed Slate Medicines and seek the Nasdaq ticker SLTE. Gregory Oakes would be CEO, Mark W. Hahn chair, and all current Fulcrum directors would resign.

## December 3 vote and the exit clauses

Fulcrum holders vote December 3 at a virtual meeting; the record date is October 28\. Approval of the share issuance and the reverse split, each by a majority of votes cast, is required to close. Holders of about 1.0% of Fulcrum have signed support agreements.

Fulcrum would owe Slate $10 million in certain termination scenarios, and Slate would owe Fulcrum $15 million. Closing is expected in the fourth quarter, with an outside date of February 28, 2027.

The vote on December 3 decides whether Fulcrum's holders take the dividend and a roughly 5% stake, or face the liquidation the board says it weighed.

Learn

- [What a Reverse Termination Fee Means: Who Pays When a Merger Collapses →](https://www.bullished.co/learn/reverse-termination-fee-meaning/)  
A reverse termination fee is paid by the buyer to the target if a merger fails on agreed terms. See how it differs from a break-up fee, with live deal examples.
- [How To Read A Merger Proxy: A Checklist For Shareholders Facing A Vote →](https://www.bullished.co/learn/merger-proxy-statement-how-to-read/)  
Facing a merger vote? Read the proxy in this order: price and payment, vote date and threshold, board background, synergy claims, then closing conditions.

### Sources

- [S-4/A — Fulcrum Therapeutics, Inc. re: Fulcrum Therapeutics, Inc. (FULC)](https://www.sec.gov/Archives/edgar/data/0001680581/000119312526444432/d127837ds4a.htm?ref=bullished.co) — SEC EDGAR

### More on Fulcrum Therapeutics

- [Fulcrum Holders Get About 5% Of Slate Deal Plus A $270 Million Dividend, Amended Filing Shows](https://www.bullished.co/fulcrum-holders-get-about-5-of-slate-deal-plus-a-270-million-dividend-amended-filing-shows-cc7bd370/)
- [Fulcrum Holders Would Keep About 5% Of Combined Company Plus A Cash Dividend Under Slate Merger](https://www.bullished.co/fulcrum-holders-would-keep-about-5-of-combined-company-plus-a-cash-dividend-under-slate-4aabb4d8/)

[All Fulcrum Therapeutics (FULC) coverage →](https://www.bullished.co/tag/fulc/)